We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: adjuvant therapy
MedXY News
EnglishTag

adjuvant therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Clinical Impact of Sentinel Lymph Node Biopsy in Atypical Endometrial Hyperplasia: Insights from a Multicenter Cohort Study
newsSentinel Lymph Node Biopsyatypical endometrial hyperplasia

Clinical Impact of Sentinel Lymph Node Biopsy in Atypical Endometrial Hyperplasia: Insights from a Multicenter Cohort Study

By MedXY|Aug 27, 2026

Sentinel lymph node biopsy in atypical endometrial hyperplasia patients identifies occult cancers and refines adjuvant treatment strategies, supporting its safe and feasible use for better risk stratification.

Optimizing Adjuvant Therapy for KIT Exon 9-Mutated Gastrointestinal Stromal Tumors: Evidence from a Global Multicenter Synthesis
Clinical Updatesadjuvant therapy
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Optimizing Adjuvant Therapy for KIT Exon 9-Mutated Gastrointestinal Stromal Tumors: Evidence from a Global Multicenter Synthesis

By MedXY|Mar 2, 2026

This review synthesizes the latest evidence on adjuvant imatinib for KIT exon 9-mutated GISTs, highlighting the landmark 2026 international study that confirms improved survival and challenges previous dosing paradigms in the adjuvant setti

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial
newsadjuvant therapyAumolertinib

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

By MedXY|Feb 19, 2026

The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial
Hematology-Oncologyadjuvant therapyCarboplatin

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

By MedXY|Jan 20, 2026

The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
Gastroenterologyadjuvant therapycamrelizumab

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

By MedXY|Jan 14, 2026

The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea

Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard
Gastroenterologyadjuvant therapyesophageal squamous cell carcinoma

Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard

By MedXY|Jan 6, 2026

A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatmen

Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial
newsadjuvant therapyEndometrial Cancer

Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial

By MedXY|Jan 6, 2026

The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standar

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care
newsadjuvant therapyConsensus

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care

By MedXY|Dec 19, 2025

The 2025 Advanced Urologic Cancer Consensus Conference (AUC3) issues practical, evidence‑informed expert recommendations on diagnosis, perioperative therapy, frontline and later‑line systemic sequencing, and special populations for RCC and

Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib
Hematology-Oncologyadjuvant therapycelecoxib

Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib

By MedXY|Dec 7, 2025

A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer
newsadjuvant therapyhead and neck oncology

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

By MedXY|Nov 22, 2025

In a multicenter cohort of 3,980 oral cavity squamous cell carcinoma patients, preoperative clinical and tumor features—including age, comorbidity, tumor subsite, size, clinical stage, and biopsy grade—predicted receipt and intensity of adj

Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)
Clinical Updatesadjuvant therapycirculating tumor DNA

Circulating Tumor DNA-Guided Adjuvant Therapy: Recent Advances and Clinical Implications (2021–2025)

By MedXY|Nov 13, 2025

This review synthesizes recent evidence (2021–2025) on circulating tumor DNA-guided adjuvant therapy, highlighting advances in personalized cancer management and emerging challenges.

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
newsadjuvant therapycolon cancer

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

By MedXY|Nov 12, 2025

The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation

De-escalated Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Cancer: Balancing Efficacy with Reduced Toxicity
Clinical Updatesadjuvant therapyHPV-associated oropharyngeal cancer

De-escalated Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Cancer: Balancing Efficacy with Reduced Toxicity

By MedXY|Oct 8, 2025

This phase 3 trial shows that de-escalated adjuvant radiotherapy reduces chronic grade 3+ toxicities compared to standard chemoradiotherapy in HPV-associated oropharyngeal cancer, potentially improving patient quality of life without compro

Clinical Updatesadjuvant therapyAspirin

Adjuvant Aspirin in PIK3CA-Mutated Colon Cancer: Insights from the SAKK 41/13 Randomized Trial

By MedXY|Oct 8, 2025

The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review
Clinical Updatesadjuvant therapyimmune checkpoint inhibitors

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY|Oct 7, 2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and

Advancing Adjuvant Therapy in Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Promising Results from Immunochemoradiation Trial
Oncologyadjuvant therapycamrelizumab

Advancing Adjuvant Therapy in Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Promising Results from Immunochemoradiation Trial

By MedXY|Oct 4, 2025

The ACCORD trial demonstrates that combining camrelizumab with chemoradiotherapy significantly improves survival outcomes in resectable extrahepatic cholangiocarcinoma and gallbladder cancer, with an acceptable safety profile.

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous-Cell Carcinoma: A Review of Recent Evidence and Clinical Implications
Clinical Updatesadjuvant therapycemiplimab

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous-Cell Carcinoma: A Review of Recent Evidence and Clinical Implications

By MedXY|Oct 4, 2025

Adjuvant cemiplimab significantly improves disease-free survival in patients with high-risk cutaneous squamous-cell carcinoma post-surgery and radiotherapy, reducing locoregional and distant recurrences compared to placebo, with manageable

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Phase 3 Trial Overview and Clinical Implications
newsadjuvant therapyhead and neck cancer

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Phase 3 Trial Overview and Clinical Implications

By MedXY|Oct 4, 2025

The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities